Zamoner Welder, Santos Camilla Andrade da Silva, Magalhães Luís Eduardo, de Oliveira Paula Gabriela Sousa, Balbi André Luis, Ponce Daniela
Botucatu School of Medicine, University São Paulo State-UNESP, Botucatu, Brazil.
Front Med (Lausanne). 2021 Feb 9;8:622577. doi: 10.3389/fmed.2021.622577. eCollection 2021.
Renal involvement is frequent in COVID-19 (4-37%). This study evaluated the incidence and risk factors of acute kidney injury (AKI) in hospitalized patients with COVID-19. This study represents a prospective cohort in a public and tertiary university hospital in São Paulo, Brazil, during the first 90 days of the COVID-19 pandemic, with patients followed up until the clinical outcome (discharge or death). There were 101 patients hospitalized with COVID-19, of which 51.9% were admitted to the intensive care unit (ICU). The overall AKI incidence was 50%; 36.8% had hematuria or proteinuria (66.6% of those with AKI), 10.2% had rhabdomyolysis, and mortality was 36.6%. Of the ICU patients, AKI occurred in 77.3% and the mortality was 65.4%. The mean time for the AKI diagnosis was 6 ± 2 days, and Kidney Disease Improving Global Outcomes (KDIGO) stage 3 AKI was the most frequent (58.9%). Acute renal replacement therapy was indicated in 61.5% of patients. The factors associated with AKI were obesity [odds ratio (OR) 1.98, 95% confidence interval (CI) 1.04-2.76, < 0.05] and the APACHE II score (OR 1.97, 95% CI 1.08-2.64, < 0.05). Mortality was higher in the elderly (OR 1.03, 95% CI 1.01-1.66, < 0.05), in those with the highest APACHE II score (OR 1.08, 95% CI 1.02-1.98, < 0.05), and in the presence of KDIGO stage 3 AKI (OR 1.11, 95% CI 1.05-2.57, < 0.05). AKI associated with severe COVID-19 in this Brazilian cohort was more frequent than Chinese, European, and North American data, and the risk factors associated with its development were obesity and higher APACHE II scores. Mortality was high, mainly in elderly patients, in those with a more severe disease manifestation, and in those who developed KDIGO stage 3 AKI.
新冠病毒病(COVID-19)患者中肾脏受累很常见(4%-37%)。本研究评估了COVID-19住院患者急性肾损伤(AKI)的发生率及危险因素。本研究为巴西圣保罗一所公立三级大学医院在COVID-19大流行的前90天进行的一项前瞻性队列研究,对患者进行随访直至临床结局(出院或死亡)。共有101例COVID-19住院患者,其中51.9%入住重症监护病房(ICU)。AKI总体发生率为50%;36.8%有血尿或蛋白尿(占AKI患者的66.6%),10.2%有横纹肌溶解,死亡率为36.6%。ICU患者中,AKI发生率为77.3%,死亡率为65.4%。AKI诊断的平均时间为6±2天,肾脏病改善全球预后(KDIGO)3期AKI最为常见(58.9%)。61.5%的患者需要进行急性肾替代治疗。与AKI相关的因素为肥胖[比值比(OR)1.98,95%置信区间(CI)1.04-2.76,<0.05]和急性生理与慢性健康状况评分系统(APACHE)II评分(OR 1.97,95%CI 1.08-2.64,<0.05)。老年人死亡率更高(OR 1.03,95%CI 1.01-1.66,<0.05),APACHE II评分最高者死亡率更高(OR 1.08,95%CI 1.02-1.98,<0.05),以及存在KDIGO 3期AKI者死亡率更高(OR 1.11,95%CI 1.05-2.57,<0.05)。在这个巴西队列中,与重症COVID-19相关的AKI比中国、欧洲和北美的数据更为常见,其发生的危险因素为肥胖和更高的APACHE II评分。死亡率很高,主要见于老年患者、疾病表现更严重的患者以及发生KDIGO 3期AKI的患者。